Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) is expected to report second quarter earnings results, before market open, on Monday 10th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 2.92 per share from revenue of $ 72.15 million.
Looking ahead, the full year loss are expected at $ 11.35 per share on the revenues of $ 288.07 million.
Previous Quarter Performance
Intercept Pharmaceuticals, Inc. recorded loss for the first quarter of $ 2.86 per share, from the revenue of $ 72.65 million. The quarterly revenues surged 39.77 percent compared with the same quarter last year. According to street consensus, ICPT was expected to report 1Q20 loss of $ 2.95 per share from revenue of $ 69.66 million. The bottom line results beat street analysts by $ 0.09 or 3.05 percent, at the same time, top line results outshined analysts by $ 2.99 million or 4.29 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Intercept Pharmaceuticals, Inc.
Stock Performance
According to the previous trading day, closing price of ICPT was $ 48.75, representing a 15.55 % increase from the 52 week low of $ 42.19 and a 61 % decrease over the 52 week high of $ 125.00.
The company has a market capital of $ 1.61 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”ICPT” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 30th June 2020, downgraded by Credit Suisse Group to Neutral from Outperform rating, with $ 59.00 target price.
- On 30th June 2020, maintained by Needham & Company LLC at Buy rating, with $ 100.00 target price.
- On 30th June 2020, downgraded by Cantor Fitzgerald to Neutral from Overweight rating.
- On 30th June 2020, downgraded by Robert W. Baird to Neutral from Outperform rating.
- On 30th June 2020, downgraded by Cowen to Market Perform from Outperform rating, with $ 47.00 target price.
Conference Call
Intercept Pharmaceuticals, Inc. will be hosting a conference call at 8:30 AM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.interceptpharma.com
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development.
